StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Edwards Lifesciences' (EW) SAPIEN XT PARTNER II Trial Met Primary Endpoint
April 3, 2016 12:20 PM
Edwards Lifesciences Corporation (NYSE: EW) announced that the randomized PARTNER II Trial comparing the SAPIEN XT valve to surgery in ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Management Comments
Next Articles
Northland Capital Markets Downgrades Edwards Lifesciences (EW) to Market Perform (Earlier)
April 5, 2016 10:27 AM
Stifel Raises Price Target on Edwards Lifesciences (EW) to $117; Reiterates Buy
April 4, 2016 10:33 AM
Edwards Lifesciences (EW) Raising Estimates, PT on Better Than Expected Sapien 3 Data - Leerink Partners
April 4, 2016 7:50 AM
BTIG Upgrades Edwards Lifesciences (EW) to Buy
April 4, 2016 7:35 AM
Edwards Lifesciences (EW) PT Raised to $98 at Credit Suisse Following Sapien Data
April 4, 2016 7:21 AM
Edwards Lifesciences (EW) PT Raised to at Jefferies Following PARTNER II Sapien 3 Data
April 4, 2016 6:45 AM
Edwards SAPIEN XT Valve Meets Primary Endpoint In PARTNER II Trial
April 2, 2016 9:00 AM
